{
  "ticker": "CDTX",
  "company_name": "Cidara Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02516904",
      "title": "A Single Ascending Dose Study of CD101 IV in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2015-07",
      "completion_date": "2015-10",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT07225959",
      "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies Following Annual Doses of CD388",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Healthy Participants",
      "start_date": "2025-10-29",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT02888197",
      "title": "Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial",
      "start_date": "2016-08-16",
      "completion_date": "2017-03-15",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT05523089",
      "title": "The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Influenza",
      "start_date": "2022-09-09",
      "completion_date": "2023-07-17",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT02734862",
      "title": "CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis",
      "start_date": "2016-07-26",
      "completion_date": "2019-07",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT06609460",
      "title": "Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Influenza",
      "start_date": "2024-09-20",
      "completion_date": "2025-09-19",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT01731353",
      "title": "FungiScope - A Global Emerging Fungal Infection Registry",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Invasive Fungal Disease",
      "start_date": "2003-03",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "University of Cologne"
    },
    {
      "nct_id": "NCT05619536",
      "title": "Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2022-10-18",
      "completion_date": "2023-07-14",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT07300085",
      "title": "A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone\u00ae HD Vaccine",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2025-11-08",
      "completion_date": "2026-05",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    },
    {
      "nct_id": "NCT02733432",
      "title": "RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial",
      "start_date": "2016-06-08",
      "completion_date": "2016-12-23",
      "enrollment": 0,
      "sponsor": "Cidara Therapeutics Inc."
    }
  ],
  "summary": {
    "total_trials": 14,
    "by_phase": {
      "PHASE1": 5,
      "PHASE2": 5,
      "": 2,
      "PHASE3": 2
    },
    "by_status": {
      "COMPLETED": 10,
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 2
    },
    "active_trials": 4,
    "completed_trials": 10,
    "conditions": [
      "Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis",
      "Candidemia, Mycoses, Fungal Infection, Invasive Candidiases",
      "Candidiasis, Vulvovaginal, Mycoses, Yeast Infection, Moniliasis, Vulvovaginal, Vaginitis, Monilial",
      "Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial",
      "Healthy",
      "Healthy Participants",
      "Influenza",
      "Invasive Fungal Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T14:00:06.504612",
    "search_query": "Cidara Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Cidara+Therapeutics,+Inc."
  }
}